相关实验视频
Updated: May 26, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
血糖目标和预防并发症
Yumiko Tsushima1, Nicholas Galloway1
1Department of Internal Medicine, University Hospitals Cleveland Medical Center, Diabetes and Metabolic Care Center, Cleveland, OH 44106, USA.
The Journal of clinical endocrinology and metabolism
|February 25, 2025
概括
有效管理糖尿病需要达到血糖指数的目标,以防止严重的并发症. 早期查和及时治疗对于阻止疾病进展和改善患者结果至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
背景情况:
- 糖尿病并发症显著影响患者的发病率,死亡率,生活质量和医疗费用.
- 通过血糖控制预防糖尿病并发症是主要的管理目标.
- 许多患者被诊断出现有的并发症,需要预防疾病进展的策略.
研究的目的:
- 审查目前用于糖尿病管理的血糖指标.
- 概述查和管理糖尿病相关并发症的方法.
- 为了提供预防糖尿病进展的策略的概述.
主要方法:
- 从1993年到2024年进行了一项全面的PubMed文献审查.
- 包括专注于糖尿病,血糖目标和微血管/宏血管并发症的研究.
- 参考来自国家糖尿病,病学和心脏病学组织的指导方针,补充了CDC和国家脏基金会的统计数据.
主要成果:
- 实现和维持血糖目标对于早期发现并发症和介入至关重要.
- 在适当的时间间隔进行定期查有助于及时管理.
- 对血糖管理的算法方法,考虑个体风险因素,有助于药物治疗选择.
结论:
- 与糖尿病相关的并发症具有严重的后果.
- 保持血糖目标,加上勤奋的查,降低风险因素和及时治疗,可以有效地阻止疾病的进展.
相关概念视频
Diabetes: Management and Pharmacotherapy
227
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
227
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
Diabetes: Symptoms, Diagnosis, and Complications
495
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
495
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
142
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
142

